98%
921
2 minutes
20
Background: Calcium carbonate is widely used as a phosphate binder in patients on maintenance hemodialysis. An unwanted side effect of calcium carbonate is hypercalcemia and vascular calcification. Oral activated charcoal (AC) is a non-selective and highly effective adsorbent. We hypothesized that AC augments the phosphate binding capacity of calcium-based agents. We performed an in vitro study to test this hypothesis.
Methods: Simulated gastric fluid and intestinal fluid were prepared with a phosphate concentration of 10 mmol/l. Different dosages of calcium chloride (0.083 g, 0.167 g, and 0.250 g), AC (0.15 g, 0.30 g, and 0.45 g) or a combination of both were added to either gastric or intestinal fluid for phosphate binding. After a reaction time of 2 hours, phosphate concentrations in the supernatant were measured, and absolute reduction and percent reduction of phosphate were calculated. The phosphate-binding abilities of calcium chloride, AC, and a combination of both were compared.
Results: In simulated intestinal fluid there was no significant difference in the percent reduction of phosphate concentrations among the different calcium chloride concentration groups (28.90 ± 2.04 vs. 33.33 ± 3.90 vs. 31.86 ± 5.23) and there was still no significant difference in phosphate concentrations among the different AC groups (3.33 ± 0.08 vs. 3.26 ± 0.01 vs. 3.36 ± 0.11). In simulated gastric fluid phosphate concentrations at each of the time points (before the reaction, 1 hour after calcium chloride was added, and 2 hours after AC was added) were not significantly different. In simulated intestinal fluid the percent decrease in phosphate concentration in the calcium chloride + AC group was significantly higher than that in the calcium chloride group (48.23 ± 5.55 vs. 30.72 ± 6.11).
Conclusions: AC alone had no phosphate-binding ability in either gastric or intestinal fluid. The phosphate-binding ability of calcium chloride was improved by AC in intestinal fluid.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5414/CN107713 | DOI Listing |
Herz
September 2025
Department of Cardiology, The Third Clinical College of Wenzhou Medical University, 326000, Wenzhou, Zhejiang, China.
Background: The protective function of the tetrandrine (TET)-mediated transient receptor potential vanilloid 2 (TRPV2) channel in myocardial ischemia/reperfusion injury (MI/RI) has been established in numerous investigations. The objective of the current study was to explain how TRPV2 further modulates downstream factors to influence the progression of MI/RI.
Methods: To this end, an MI/RI model in rats and a hypoxia-reoxygenation (H/R) cell model in H9c2 cells were constructed.
Vet World
July 2025
Akkhraratchakumari Veterinary College, Walailak University, Nakhon Si Thammarat, 80160, Thailand.
Background And Aim: Probiotic viability remains a critical challenge during gastrointestinal (GI) transit, storage, and feed processing. Conventional encapsulation materials often fail under acidic and thermal stress. This study aimed to develop and characterize a novel, eco-friendly microencapsulation system using (FP) seed extract as a natural encapsulating matrix for (LP) WU2502, enhancing its functional resilience and storage stability.
View Article and Find Full Text PDFMol Ther
September 2025
Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France. Electronic address:
Patients with cystic fibrosis (CF) who are non-responsive to treatments due to specific mutations need alternative CFTR-independent therapies. This study aims to assess the impact of TMEM16a expression by a specific oligonucleotide (TMEM16a ASO) on dysregulated parameters in CF, which will help prepare for preclinical studies. In this study, we analyzed the effects of TMEM16a oligonucleotide within a CF context by evaluating the impact, optimal administration route, toxicity, and specificity in primary cells and various mouse models.
View Article and Find Full Text PDFN Z Vet J
September 2025
Diagnostics, Readiness and Surveillance, Biosecurity New Zealand, Ministry for Primary Industries, Wellington, New Zealand.
Case History: In 2023, 160/245 (65%) 2-year-old KiwiCross dairy heifers from a seasonally calving Otago herd developed severe granular vulvovaginitis after calving.
Clinical Findings: Affected heifers presented 3-12 days post-calving with tail elevation, vaginal discharge and, in most cases, vulval swelling. Heifers were afebrile although some were inappetent.
MedComm (2020)
September 2025
The activation of nucleotide oligomerization domain-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is implicated in the pathogenesis of various inflammatory diseases. The natural product oridonin possesses a novel mechanism for NLRP3 inhibition and a unique binding mode with NLRP3, but its poor anti-inflammatory activity limits further application. After virtual screening of diverse natural product libraries, dehydrocostus lactone (DCL) was considered as a potential NLRP3 inhibitor.
View Article and Find Full Text PDF